Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.89 EUR | 0.00% | +7.23% | +29.74% |
04-30 | ITALY GROWTH WINNERS & LOSERS: Plants at the top; AATech bearish | AN |
04-12 | Farmacosmo S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The stock, which is currently worth 2024 to 0.5 times its sales, is clearly overvalued in comparison with peers.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Department Stores
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+29.74% | 37.28M | - | ||
+15.37% | 51.69B | B | ||
+37.34% | 39.73B | - | ||
+14.21% | 10.11B | B | ||
+17.95% | 8.7B | C | ||
-21.37% | 7.31B | C | ||
+11.21% | 6.38B | B- | ||
-2.90% | 5.78B | D+ | ||
+13.80% | 5.38B | C | ||
-51.24% | 3.52B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- COSMO Stock
- Ratings Farmacosmo S.p.A.